(Q37794267)

23 August 2017

title

Pathophysiology of multiple sclerosis and the place of teriflunomide (English)

1 reference

23 August 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

R. Gold

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20880295

22 July 2024

J. S. Wolinsky

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20880295

22 July 2024

language of work or name

English

0 references

publication date

29 September 2010

1 reference

full work available at URL

23 August 2017

https://doi.org/10.1111/j.1600-0404.2010.01444.x

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20880295

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-0404.2010.01444.x

22 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2010.01444.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0404.2010.01444.x/fullpdf

22 July 2024

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2010.01444.X

Acta Neurologica Scandinavica

22 July 2024

published in

1 reference

23 August 2017

volume

124

1 reference

23 August 2017

issue

2

1 reference

23 August 2017

page(s)

75-84

1 reference

The spectrum of multiple sclerosis: new lessons from pathology.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Drug treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Epidemiology of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Primary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Multiple sclerosis--the plaque and its pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

New concepts in the immunopathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Immunomodulatory effects of Vitamin D in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Genetics of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Genetics and natural history of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

The complex genetics of multiple sclerosis: pitfalls and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

The role of CD4 T cells in the pathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Autoaggressive effector T cells in the course of experimental autoimmune encephalomyelitis visualized in the light of two-photon microscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Immunological basis for the development of tissue inflammation and organ-specific autoimmunity in animal models of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Oral disease-modifying treatments for multiple sclerosis: the story so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Glatiramer acetate in multiple sclerosis: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Mechanism of action for leflunomide in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

In vitro and in vivo pharmacological models to assess demyelination and remyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2010.01444.X

Genetics of multiple sclerosis

21 January 2018

17

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2010.01444.X

Multiple susceptibility loci for multiple sclerosis

22 July 2024

20

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2010.01444.X

Emerging oral drugs for multiple sclerosis

22 July 2024

33

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2010.01444.X

Regulation of B cell function by the immunosuppressive agent leflunomide

22 July 2024

37

1 reference

https://api.crossref.org/works/10.1111/J.1600-0404.2010.01444.X

22 July 2024

Identifiers

1 reference

23 August 2017

1 reference